Executive Leadership
Arthur Kuan
Chief Executive Officer
Ambaw Bellete
President and Chief Operating Officer
Vijay Kasturi, MD
Chief Medical
Officer
Swapnil Bhargava
Chief Technical
Officer
Stephen DiPalma
Chief Financial
Officer
Board of Directors
Arthur Kuan
Chief Executive Officer
Brian Liu
Managing Director, Longitude Capital
Jim Mulé, PhD
Director of Cell-based Therapies, Moffitt Cancer Center
Leonard Post, PhD
Chief Scientific Officer, Vivace Therapeutics
Simone Song
Senior Partner, ORI Capital
Victor Tong, Jr.
Partner, Decheng Capital
Arthur Kuan
Chief Executive Officer
Ambaw Bellete
President and Chief Operating Officer
Ambaw serves as President & Chief Operating Officer at CG Oncology where he has responsibility for the overall commercial organization comprised of sales and marketing, communications and advocacy, business analytics and operations, health outcomes research, and patient access. In addition to leading our business development, corporate strategy, quality, regulatory affairs, and supply chain organization. Ambaw has over 30 years of experience in the biotech industry, and he has a proven track record of success building and leading multidisciplinary teams from pre-launch to commercialization. He is passionate about bringing new solutions to the bladder cancer community and maintaining a personal and compassionate focus on patients, their caregivers, and families. He previously served as CEO of Lion Healthcare Strategies, the Chief Operating Officer at FerGene, and was also President of Photocure, a company focused on photodynamic therapy to treat bladder cancer. He has also held several global leadership positions with biotech and medical device companies including as President of MCS. He started his biotech career at The Upjohn Company (now Pfizer) and then Sanofi, where he held diverse senior leadership roles. Ambaw currently serves as Chairman of the Board for OncoSTING and is a board member of Axiom Reach Foundation.
Vijay Kasturi, MD
Chief Medical Officer
Swapnil Bhargava, PhD
Chief Technical Officer
Swapnil is the Chief Technical Officer at CG Oncology. He is responsible for building CMC functions including process development, MSAT, manufacturing, regulatory filings, and optimal delivery of cretostimogene grenadenorepvec for clinical studies and commercial supply following approval. He has supported multiple INDs and BLAs and has contributed to bringing multiple modalities to clinic and market: before joining CG Oncology Swapnil was the Senior Vice President of CMC Development and GMP Manufacturing at AbCellera, leading the TechOps team. Prior to that, he was the VP for drug substance process development at SeaGen. There he was responsible for leading cell line development, upstream, downstream and conjugation process development and analytical sciences departments for early and late-stage drug development. Earlier, while at Amgen he had led process development efforts for different modalities, including biosimilars. Swapnil has a doctorate in Chemical Engineering from University of Maryland and a BS/MS from the Indian Institute of Technology (IIT) Delhi.
Stephen DiPalma
Chief Financial Officer
Arthur Kuan
Chief Executive Officer
Victor Tong, Jr.
Partner, Decheng Capital
Brian Liu
Managing Director, Longitude Capital
Jim Mulé, PhD
Director of Cell-based Therapies, Moffitt Cancer Center
Leonard Post, PhD
Chief Scientific Officer, Vivace Therapeutics
Simone Song
Senior Partner, ORI Capital